Sherritt Provides Notice of First Quarter 2026 Results Conference Call

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO--(BUSINESS WIRE)-- Sherritt International Corporation (“Sherritt” or the “Corporation”) (TSX: S) will release its first quarter 2026 results after market close on May 12, 2026. Senior management will host a conference call and webcast on May 13, 2026 at 10:00 am ET to review Sherritt’s first quarter 2026 financial and operational performance.

Dial-in and Webcast Details:

A recording of the webcast will be available on Sherritt’s website following the conference call.

About Sherritt

Sherritt is a world leader in using hydrometallurgical processes to mine and refine nickel and cobalt – metals deemed critical for the energy transition. Leveraging its technical expertise and decades of experience in critical minerals processing, Sherritt is committed to expanding domestic refining capacity and reducing reliance on foreign sources. The Corporation operates a strategically important refinery in Alberta, Canada, recognized as the only significant cobalt refinery and one of just three nickel refineries in North America. Sherritt’s Moa Joint Venture produces cost competitive critical minerals while maintaining high sustainability standards and has an estimated mine life of approximately 25 years.

The Corporation’s Power division, through its ownership in Energas, is the largest independent energy producer in Cuba, processing domestically sourced raw natural gas to generate electricity for sale to the Cuban national electrical grid. Sherritt’s common shares are listed on the Toronto Stock Exchange under the symbol “S”.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421582929/en/

For further information, please contact:
Tom Halton
Director, Investor Relations and Corporate Affairs
Email: [email protected]
Telephone: (416) 935-2451
www.sherritt.com

Source: Sherritt International Corporation

You May Also Be Interested In

• Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
• Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
• Two Giving Programs Award $600 and Free AC to Valley Residents